Terms: = Pancreatic cancer AND PBRM1, BAF180, 55193, PB1, MGC156156, MGC156155
23 results:
1. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
[TBL] [Abstract] [Full Text] [Related]
2. Impact of Mutations in Subunit Genes of the Mammalian SWI/SNF Complex on Immunological Tumor Microenvironment.
Hozumi C; Iizuka A; Ikeya T; Miyata H; Maeda C; Ashizawa T; Nagashima T; Urakami K; Shimoda Y; Ohshima K; Muramatsu K; Sugino T; Shiomi A; Ohde Y; Bando E; Furukawa K; Sugiura T; Mukaigawa T; Nishimura S; Hirashima Y; Mitsuya K; Yoshikawa S; Tsubosa Y; Katagiri H; Niwakawa M; Yamaguchi K; Kenmotsu H; Akiyama Y
Cancer Genomics Proteomics; 2024; 21(1):88-101. PubMed ID: 38151294
[TBL] [Abstract] [Full Text] [Related]
3. Genetic and Epigenetic Characteristics in Isolated pancreatic Metastases of Clear-Cell Renal Cell Carcinoma.
Sellner F; Compérat E; Klimpfinger M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003482
[TBL] [Abstract] [Full Text] [Related]
4. A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
Janku F; Javle MM; Sen S; Pant S; Bramwell LG; Subbiah V; Way T; Wages DS; Wheeler CA; Suzuki T; Saeki K; Subach RA; Madden T; Maier G; Johansen MJ; Cheung K; Falchook GS
Cancer; 2023 May; 129(10):1537-1546. PubMed ID: 36882377
[TBL] [Abstract] [Full Text] [Related]
5. pbrm1 presents a potential prognostic marker and therapeutic target in duodenal papillary carcinoma.
He X; Xu J; Niu N; Xu G; Zhu H; Liu Z; Mou Y; Qian Z; Wang H; Hu J; Ma T; Ma J; Tao H
Clin Transl Med; 2022 Oct; 12(10):e1062. PubMed ID: 36178086
[TBL] [Abstract] [Full Text] [Related]
6. Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma.
Mafficini A; Simbolo M; Shibata T; Hong SM; Pea A; Brosens LA; Cheng L; Antonello D; Sciammarella C; Cantù C; Mattiolo P; Taormina SV; Malleo G; Marchegiani G; Sereni E; Corbo V; Paolino G; Ciaparrone C; Hiraoka N; Pallaoro D; Jansen C; Milella M; Salvia R; Lawlor RT; Adsay V; Scarpa A; Luchini C
Mod Pathol; 2022 Dec; 35(12):1929-1943. PubMed ID: 36056133
[TBL] [Abstract] [Full Text] [Related]
7. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Characterization of KRAS Wild-type Tumors in Patients with pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract] [Full Text] [Related]
9. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311
[TBL] [Abstract] [Full Text] [Related]
10. pancreatic tropism of metastatic renal cell carcinoma.
Singla N; Xie Z; Zhang Z; Gao M; Yousuf Q; Onabolu O; McKenzie T; Tcheuyap VT; Ma Y; Choi J; McKay R; Christie A; Torras OR; Bowman IA; Margulis V; Pedrosa I; Przybycin C; Wang T; Kapur P; Rini B; Brugarolas J
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271170
[TBL] [Abstract] [Full Text] [Related]
11. Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells.
Enane FO; Saunthararajah Y; Korc M
Cell Death Dis; 2018 Sep; 9(9):912. PubMed ID: 30190481
[TBL] [Abstract] [Full Text] [Related]
12. Integrated Genomic Characterization of pancreatic Ductal Adenocarcinoma.
;
Cancer Cell; 2017 Aug; 32(2):185-203.e13. PubMed ID: 28810144
[TBL] [Abstract] [Full Text] [Related]
13. pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
Basturk O; Berger MF; Yamaguchi H; Adsay V; Askan G; Bhanot UK; Zehir A; Carneiro F; Hong SM; Zamboni G; Dikoglu E; Jobanputra V; Wrzeszczynski KO; Balci S; Allen P; Ikari N; Takeuchi S; Akagawa H; Kanno A; Shimosegawa T; Morikawa T; Motoi F; Unno M; Higuchi R; Yamamoto M; Shimizu K; Furukawa T; Klimstra DS
Mod Pathol; 2017 Dec; 30(12):1760-1772. PubMed ID: 28776573
[TBL] [Abstract] [Full Text] [Related]
14. pbrm1 loss is a late event during the development of cholangiocarcinoma.
Luchini C; Robertson SA; Hong SM; Felsenstein M; Anders RA; Pea A; Nottegar A; Veronese N; He J; Weiss MJ; Capelli P; Scarpa A; Argani P; Kapur P; Wood LD
Histopathology; 2017 Sep; 71(3):375-382. PubMed ID: 28394406
[TBL] [Abstract] [Full Text] [Related]
15. The Roles of Chromatin Remodeling Genes in pancreatic-Biliary Malignancies.
Luchini C; Nottegar A
Crit Rev Oncog; 2017; 22(5-6):471-479. PubMed ID: 29604925
[TBL] [Abstract] [Full Text] [Related]
16. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and pbrm1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
[TBL] [Abstract] [Full Text] [Related]
17. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.
Fujimoto A; Furuta M; Shiraishi Y; Gotoh K; Kawakami Y; Arihiro K; Nakamura T; Ueno M; Ariizumi S; Nguyen HH; Shigemizu D; Abe T; Boroevich KA; Nakano K; Sasaki A; Kitada R; Maejima K; Yamamoto Y; Tanaka H; Shibuya T; Shibata T; Ojima H; Shimada K; Hayami S; Shigekawa Y; Aikata H; Ohdan H; Marubashi S; Yamada T; Kubo M; Hirano S; Ishikawa O; Yamamoto M; Yamaue H; Chayama K; Miyano S; Tsunoda T; Nakagawa H
Nat Commun; 2015 Jan; 6():6120. PubMed ID: 25636086
[TBL] [Abstract] [Full Text] [Related]
18. Genetic variants in the SWI/SNF complex and smoking collaborate to modify the risk of pancreatic cancer in a Chinese population.
Zhu B; Tian J; Zhong R; Tian Y; Chen W; Qian J; Zou L; Xiao M; Shen N; Yang H; Lou J; Qiu Q; Ke J; Lu X; Song W; Li H; Liu L; Wang L; Miao X
Mol Carcinog; 2015 Sep; 54(9):761-8. PubMed ID: 24585446
[TBL] [Abstract] [Full Text] [Related]
19. The clinical significance of SWI/SNF complex in pancreatic cancer.
Numata M; Morinaga S; Watanabe T; Tamagawa H; Yamamoto N; Shiozawa M; Nakamura Y; Kameda Y; Okawa S; Rino Y; Akaike M; Masuda M; Miyagi Y
Int J Oncol; 2013 Feb; 42(2):403-10. PubMed ID: 23229642
[TBL] [Abstract] [Full Text] [Related]
20. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
Shain AH; Giacomini CP; Matsukuma K; Karikari CA; Bashyam MD; Hidalgo M; Maitra A; Pollack JR
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):E252-9. PubMed ID: 22233809
[TBL] [Abstract] [Full Text] [Related]
[Next]
